P
Phil Wells
Researcher at Ottawa Hospital Research Institute
Publications - 43
Citations - 7474
Phil Wells is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Pulmonary embolism & Warfarin. The author has an hindex of 19, co-authored 43 publications receiving 6782 citations. Previous affiliations of Phil Wells include Ottawa Hospital & University of Ottawa.
Papers
More filters
Journal ArticleDOI
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more
TL;DR: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Journal ArticleDOI
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Barry F. Jacobson,Erich Minar,Jaromir Chlumsky,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Alexander T. Cohen,Scott D. Berkowitz,Bruce L. Davidson,Frank Misselwitz,Gary E. Raskob,Annelise Segers +11 more
TL;DR: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.
Journal ArticleDOI
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Buller,Hervé Decousus,Michael A. Grosso,Saskia Middeldorp,Martin H. Prins,Gary E. Raskob,Sebastian Schellong,Annelise Segers,Minggao Shi,Peter Verhamme,Phil Wells +10 more
TL;DR: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism.
Journal ArticleDOI
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor
Clive Kearon,Jeffrey S. Ginsberg,David Anderson,Michael J. Kovacs,Phil Wells,Jim A. Julian,Betsy MacKinnon,Catherine Demers,James D. Douketis,Alexander G.G. Turpie,P. Van Nguyen,David Green,Jeannine Kassis,Susan R. Kahn,Susan Solymoss,Louis Desjardins,William Geerts,Marilyn Johnston,J. I. Weitz,Jack Hirsh,Michael Gent +20 more
TL;DR: Duration of anticoagulant therapy for venous thromboembolism provoked by a transient risk factor should not be reduced from 3 months to 1 month as this is likely to increase recurrent venousThromboEmbolism without achieving a clinically important decrease in bleeding.
Journal ArticleDOI
Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
TL;DR: This study supports the safety and effectiveness of dalteparin in the treatment of upper extremity DVT and given that these patients were treated as outpatients, there is a potential for huge cost savings.